drugset / Trial / NCT02407210

Efficacy and Safety of Azilsartan Compared to Olmesartan Medoxomil in Chinese Participants With Grade I or II Essential Hypertension

NCT02407210

Phase 3 Unknown 304 enrolled Jiangsu HengRui Medicine Co., Ltd.
RandomizedParallel-groupTriple-blindTreatment

Summary

To investigate the efficacy and safety of azilsartan compared to olmesartan medoxomil in patients with grade I or II essential hypertension

Timeline

Start
2015-01
Primary completion
2015-10
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Azilsartan Unknown 20 mg Oral
Subject Azilsartan Unknown 40 mg Oral
Comparator Olmesartan medoxomil Unknown 20 mg Oral
Comparator Olmesartan medoxomil Unknown 40 mg Oral